Taysha Gene Therapies (TSHA) Other Non-Current Assets (2021 - 2026)

Taysha Gene Therapies has disclosed Other Non-Current Assets across 6 years of filings, most recently posting $2.8 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $2.8 million, up 6.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 6.31% YoY), and the FY2025 annual result was $2.3 million, up 966.82% from the prior year.
• Other Non-Current Assets came in at $2.8 million for Q1 2026 at Taysha Gene Therapies, up from $2.3 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q1 2026 to a low of $184000.0 in Q3 2025.
• The 5-year median for Other Non-Current Assets is $2.6 million (2023), against an average of $2.3 million.
• Peak annual rise in Other Non-Current Assets reached 966.82% in 2025, while the deepest fall reached 92.92% in 2025.
• Taysha Gene Therapies' Other Non-Current Assets stood at $2.6 million in 2022, then dropped by 1.4% to $2.6 million in 2023, then slumped by 91.65% to $217000.0 in 2024, then soared by 966.82% to $2.3 million in 2025, then rose by 19.4% to $2.8 million in 2026.
• The last three Other Non-Current Assets figures came in at $2.8 million (Q1 2026), $2.3 million (Q4 2025), and $184000.0 (Q3 2025), per Business Quant data.